The field of targeted therapeutic radioconjugates is rapidly expanding, promising significant advancements in cancer treatment. In contrast to antibodies, radioconjugates benefit from shorter half-lives, minimizing radiation toxicity to healthy tissues. With a focus on binders of low molecular weight (< 50 kDa), such as small molecules, peptides, and antibody fragments, these radioconjugates demonstrate rapid renal clearance, albeit with an increased likelihood of elevated kidney retention based on their physicochemical characteristics.
AstraZeneca has ...